Poongjeon Pharmacy KRX:298060KOSDAQ
에스씨엠생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days5
DART filings, 7 days1
Articles tracked5since Sep 11
Poongjeon Pharmacy (에스씨엠생명과학) appeared in 5 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 26 with 4 articles.
Filing signals Private placement Dilution risk 4 quarters of losses Screener
Poongjeon Pharmacy quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 check units | ₩12.0bn | – | −₩986m | −₩3.9bn |
| Q1 2026 check units | ₩15.2bn | – | −₩1.5bn | −₩1.8bn |
| Q4 2025 derived check units | ₩12.1bn | – | −₩1.2bn | ₩804m |
| Q3 2025 check units | ₩10.5bn | – | −₩940m | −₩895m |
| Q2 2025 | ₩639m | +139.5% | −₩903m margin −141.3% | ₩4m |
| Q1 2025 | ₩574m | +152.1% | −₩1.5bn margin −263.3% | −₩1.5bn |
| Q4 2024 derived | ₩160m | -28.8% | −₩2.8bn | −₩3.6bn |
| Q3 2024 | ₩170m | -40.1% | −₩3.0bn | −₩3.1bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Poongjeon Pharmacy top stories 2 weeks, by number of outlets
- 1
- 2
Latest Poongjeon Pharmacy news Korean headlines
-
풍전약품, 30억원 제3자배정 유상증자
3 more on this story · 3 outlets
- 풍전약품, 30억원 규모 제3자배정 유상증자 결정…운영자금 확보CBC뉴스 · Oct 26 16:17
- 풍전약품, 30억 규모 제3자배정 유상증자뉴시스경제 · Oct 26 16:25
- 풍전약품, 30억원 규모 유상증자 실시매일경제 · Oct 26 17:53